VRTX · Vertex Pharmaceuticals Inc / Ma

$551.95 +23.76 (+4.50%)

Market Cap

$133.88B

253.46M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Reshma Kewalramani	CEO and President	$1,600,000	—	$15,002,270	—	$4,118,640	$423,351	$21,144,261
Stuart Arbuckle	Former EVP & Chief Operating Officer	$521,486	—	$9,341,927	—	—	$132,934	$9,996,347
Charles Wagner	EVP & Chief Operating and Financial Officer	$974,808	—	$5,250,817	—	$1,965,000	$51,184	$8,241,809
Nia Tatsis	EVP & Chief Regulatory and Quality Officer	$750,000	—	$4,900,522	—	$1,282,163	$42,235	$6,974,920
Amit Sachdev	EVP & Chief Patient and External Affairs Officer	$700,000	—	$4,900,522	—	$1,155,420	$21,301	$6,777,243
Carmen Bozic	EVP & Chief Medical Officer	$835,000	—	$4,375,531	—	$1,378,251	$57,539	$6,646,321

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Reshma Kewalramani	CEO and President	$1,541,154	—	$15,002,202	—	$4,941,600	$53,712	$21,538,668
Stuart Arbuckle	EVP & Chief Operating Officer	$941,154	—	$6,234,857	—	$2,130,000	$77,452	$9,383,463
Charles Wagner	EVP & Chief Financial Officer	$876,443	—	$5,250,328	—	$1,821,150	$51,519	$7,999,440
David Altshuler	EVP & Chief Scientific Officer	$876,443	—	$5,250,328	—	$1,456,920	$53,787	$7,637,478
Nia Tatsis	EVP & Chief Regulatory and Quality Officer	$691,154	—	$5,250,328	—	$1,341,900	$50,934	$7,334,316

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Reshma Kewalramani	CEO and President	$1,500,000	—	$15,001,894	—	$4,050,000	$42,547	$20,594,441
Stuart Arbuckle	EVP & Chief Operating Officer	$900,000	—	$6,234,712	—	$1,822,500	$41,737	$8,998,949
Charles Wagner	EVP & Chief Financial Officer	$825,000	—	$5,250,552	—	$1,256,063	$40,136	$7,371,751
Jeffrey Leiden	Executive Chairman	—	—	$6,500,260	—	—	$95,022	$6,595,282
David Altshuler	EVP & Chief Scientific Officer	$825,000	—	$4,375,089	—	$1,299,375	$41,636	$6,541,100

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Reshma Kewalramani	CEO and President	$1,396,154	—	$10,640,784	—	$3,784,500	$43,059	$15,864,497
Stuart Arbuckle	EVP & Chief Operating Officer	$900,000	—	$12,294,259	—	$1,761,750	$43,097	$14,999,106
Jeffrey Leiden	Executive Chairman	—	—	$8,500,250	—	—	$92,930	$8,593,180
David Altshuler	EVP & Chief Scientific Officer	$810,577	—	$4,500,090	—	$1,172,325	$42,137	$6,525,129
Charles Wagner	EVP & Chief Financial Officer	$793,269	—	$3,750,197	—	$1,239,315	$28,830	$5,811,611

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Reshma Kewalramani	CEO and President	$1,221,923	—	$10,924,599	—	$3,016,570	$35,764	$15,198,856
Jeffrey Leiden	Executive Chairman	$242,308	—	$7,875,259	—	—	$39,672	$8,157,239
Stuart Arbuckle	EVP & Chief Operating Officer	$842,308	—	$5,250,173	—	$1,676,700	$40,960	$7,810,141
Nia Tatsis	EVP & Chief Regulatory and Quality Officer	$550,000	—	$5,250,173	—	$743,820	$40,035	$6,584,028
David Altshuler	EVP & Chief Scientific Officer	$756,731	—	$4,375,430	—	$1,159,200	$39,976	$6,331,337
Charles Wagner	EVP & Chief Financial Officer	$729,615	—	$4,375,430	—	$1,078,539	$40,348	$6,223,932

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jeffrey Leiden	Executive Chairman	$1,121,539	—	$13,335,168	—	$1,973,400	$43,138	$16,473,245
Reshma Kewalramani	CEO and President	$1,097,308	—	$5,250,411	—	$2,723,292	$40,348	$9,111,359
Stuart Arbuckle	EVP & Chief Operating Officer	$830,769	—	$5,250,411	—	$1,159,200	$42,598	$7,282,978
David Altshuler	EVP & Global Research and Chief Scientific Officer	$752,885	—	$5,250,411	—	$1,015,508	$41,780	$7,060,584
Michael Parini	(EVP & Chief Administrative, Legal and Business Development Officer through March 1, 2021)	$830,769	—	$4,375,585	—	$1,081,920	$67,404	$6,355,678
Charles Wagner	EVP & Chief Financial Officer	$726,923	—	$4,375,585	—	$946,680	$41,202	$6,090,390

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jeffrey Leiden	Executive Chairman	$1,300,000	—	$9,334,681	$4,572,039	$3,510,000	$73,265	$18,789,985
Stuart Arbuckle	EVP & Chief Operating Officer	$770,962	—	$3,215,952	$1,575,011	$1,260,000	$37,608	$6,859,533
Reshma Kewalramani	CEO and President	$702,308	—	$3,215,952	$1,575,011	$1,260,000	$63,665	$6,816,936
Amit Sachdev	EVP & Chief Patient Officer	$540,750	—	$3,215,952	$1,575,011	$823,292	$42,048	$6,197,053
Michael Parini	(EVP & Chief Administrative, Legal and Business Development Officer through March 1, 2021)	$785,481	—	$2,679,897	$1,312,509	$1,218,000	$43,610	$6,039,497
Charles Wagner	EVP & Chief Financial Officer	$492,692	$140,000	$1,225,383	$600,039	$992,250	$36,849	$3,487,213
Paul M. Silva	SVP & Corporate Controller (Interim CFO for a portion of 2019)	$442,569	—	$1,895,084	$468,803	$378,000	$13,401	$3,197,857
Ian F. Smith	Former EVP & Chief Operating Officer and Former Interim Chief Financial Officer	$75,192	—	—	—	—	$1,376,648	$1,451,840

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jeffrey Leiden	Executive Chairman (CEO and President through March 31, 2020)	$1,300,000	—	$9,800,288	$4,243,973	$3,440,151	$14,735	$18,799,147
Amit Sachdev	EVP & Chief Patient Officer	$540,750	—	$3,150,448	$1,364,130	$602,261	$20,672	$5,678,261
Michael Parini	(EVP & Chief Administrative, Legal and Business Development Officer through March 1, 2021)	$746,923	—	$2,625,244	$1,136,785	$823,384	$29,000	$5,372,336
Stuart Arbuckle	EVP & Chief Commercial and Operations Officer	$721,923	—	$2,625,244	$1,136,785	$824,175	$38,965	$5,347,092
Ian F. Smith	Former EVP & Chief Operating Officer and Former Interim Chief Financial Officer	$850,000	—	$2,625,244	$1,136,785	—	$14,105	$4,626,134

Fiscal 2017

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jeffrey Leiden	Executive Chairman (CEO and President through March 31, 2020)	$1,300,000	—	$8,750,114	$3,700,877	$3,463,200	$13,110	$17,227,301
Ian F. Smith	Former EVP & Chief Operating Officer and Former Interim Chief Financial Officer	$848,077	—	$2,625,016	$1,110,263	$1,339,770	$13,110	$5,936,236
Amit Sachdev	EVP & Chief Patient Officer	$540,750	—	$2,625,016	$1,110,263	$600,233	$10,001	$4,886,263
Stuart Arbuckle	EVP & Chief Commercial Officer	$700,000	—	$2,100,013	$888,210	$699,300	$13,110	$4,400,633

Executive changes

Person	Role	Change	Effective	Filed
Nancy Thornberry	member of the Company's Board of Directors	Appointed	2026-05-13	2026-05-13
Jennifer Schneider	member of the Company's Board of Directors	Appointed	2026-05-13	2026-05-13
Bruce Sachs	member of the Company's Board of Directors	Appointed	2026-05-13	2026-05-13
Diana McKenzie	member of the Company's Board of Directors	Appointed	2026-05-13	2026-05-13
Jeffrey Leiden	member of the Company's Board of Directors	Appointed	2026-05-13	2026-05-13
Michel Lagarde	member of the Company's Board of Directors	Appointed	2026-05-13	2026-05-13
Reshma Kewalramani	member of the Company's Board of Directors	Appointed	2026-05-13	2026-05-13
Alan Garber	member of the Company's Board of Directors	Appointed	2026-05-13	2026-05-13
Lloyd Carney	member of the Company's Board of Directors	Appointed	2026-05-13	2026-05-13
Sangeeta Bhatia	member of the Company's Board of Directors	Appointed	2026-05-13	2026-05-13
Duncan J. McKechnie	Chief Commercial Officer	Appointed	2025-07-01	2025-02-10
Charles F. Wagner, Jr.	Chief Operating Officer	Appointed	2025-07-01	2025-02-10
Stuart A. Arbuckle	Executive Vice President and Chief Operating Officer	Retired	2025-07-01	2025-02-10
Nancy Thornberry	member of the board of directors	Appointed	2023-12-05	2023-12-05
Michel Lagarde	member of the board of directors	Appointed	2023-10-05	2023-10-05

Key facts CIK 875320 CUSIP 92532F100 13F (30d) 1534 filings 1490 filers Visit website Investor relations